Charles River Laboratories International, Inc. (NYSE: CRL) reported Q4 EPS of $0.69, $0.13 better than the analyst estimate of $0.56. Revenue for the quarter came in at $291 million versus the consensus estimate of $282.76 million.

Charles River Laboratories International, Inc. reaffirmed FY2012 guidance.

For earnings history and earnings-related data on Charles River Laboratories International, Inc. (CRL) click here.

Earnings Guidance